• Home
  • Press
  • Contact
  • Menu
  • Skip to right header navigation
  • Skip to main content
  • Skip to primary sidebar

TearClear logo

Preservative-free ophthalmic drug delivery

  • Home
  • Press
  • Contact

Press Releases

  • 2022
  • 2021
  • 2020
  • 2019
  • 2017
  • Sep 29, 2022
    TearClear Announces Positive Topline Results from CLEAR Phase 3 Study for the Treatment of Glaucoma with TC-002 (latanoprost ophthalmic solution 0.005%)
  • Feb 1, 2022
    TearClear announces the successful initiation of its TC-002 Latanoprost Ophthalmic Solution Phase 3 trial
  • Aug 24, 2021
    TearClear Files Investigational New Drug (IND) Application to Begin its Clinical Trial for TC-002 Latanoprost Ophthalmic Solution, 0.005%
  • Dec 1, 2020
    TearClear Announces Successful Completion of Pre-IND Meeting with the FDA for a Preservative Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucoma
  • Sep 29, 2020
    TearClear Appoints Robert Bailey to Board of Directors
  • Aug 11, 2020
    TearClear Raises $22 Million to Advance Multiple Clinical Programs in Development
  • May 20, 2020
    TearClear appoints Dr. Amir Shojaei Chief Development Officer
  • Apr 15, 2020
    TearClear appoints Robert J. Dempsey Chief Executive Officer
  • May 29, 2019
    TearClear Appoints Chief Scientific and Innovation Officer
  • May 30, 2017
    TearClear Completes $4.5 Million Series A Financing and Introduces Leadership Team of Accomplished Ophthalmology Veterans
FacebookTweetLinkedInEmailPrint

Primary Sidebar

Press

  • Press Releases
    • TearClear Raises $22 Million to Advance Multiple Clinical Programs in Development
    • TearClear Appoints Robert Bailey to Board of Directors
    • TearClear Announces Successful Completion of Pre-IND Meeting with the FDA for a Preservative Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucoma
    • TearClear Files Investigational New Drug (IND) Application to Begin its Clinical Trial for TC-002 Latanoprost Ophthalmic Solution, 0.005%
    • TearClear announces the successful initiation of its TC-002 Latanoprost Ophthalmic Solution Phase 3 trial
    • TearClear Announces Positive Topline Results from CLEAR Phase 3 Study for the Treatment of Glaucoma with TC-002 (latanoprost ophthalmic solution 0.005%)
    • TearClear Completes $4.5 Million Series A Financing and Introduces Leadership Team of Accomplished Ophthalmology Veterans
    • TearClear appoints Robert J. Dempsey Chief Executive Officer
    • TearClear appoints Dr. Amir Shojaei Chief Development Officer
    • TearClear Appoints Chief Scientific and Innovation Officer
  • In the News
  • Interviews
  • Downloads

Copyright © 2017–2023 TearClear Corp · All Rights Reserved · Design and development by Sky Dog Technologies

Share this ArticleLike this article? Email it to a friend!

Email sent!